266 related articles for article (PubMed ID: 20304212)
1. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
Mártinez JM; Pulido LB; Bellido CB; Usero DD; Aguilar LT; Moreno JL; Artacho GS; Díez-Canedo JS; Gómez LM; Bravo MA
Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation.
Alamo JM; Barrera L; Casado MD; Bernal C; Marin LM; Suarez G; Sanchez-Moreno L; Jimenez R; Suarez-Grau JM; Sousa JM; Cordero E; Gomez-Bravo MA
Transplant Proc; 2009; 41(6):2181-3. PubMed ID: 19715866
[TBL] [Abstract][Full Text] [Related]
3. Everolimus in clinical practice in long-term liver transplantation: an observational study.
Casanovas T; Argudo A; Peña-Cala MC
Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
[TBL] [Abstract][Full Text] [Related]
4. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
5. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
6. Indications and management of everolimus after liver transplantation.
Bilbao I; Sapisochin G; Dopazo C; Lazaro JL; Pou L; Castells L; Caralt M; Blanco L; Gantxegi A; Margarit C; Charco R
Transplant Proc; 2009; 41(6):2172-6. PubMed ID: 19715864
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement.
Lang UE; Heger J; Willbring M; Domula M; Matschke K; Tugtekin SM
Transplant Proc; 2009 Dec; 41(10):4285-8. PubMed ID: 20005385
[TBL] [Abstract][Full Text] [Related]
8. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
Kahan BD
Transplant Proc; 2008 Dec; 40(10 Suppl):S17-20. PubMed ID: 19100899
[TBL] [Abstract][Full Text] [Related]
9. Safety of an immunosuppressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence.
Castroagudín JF; Molina E; Tomé S; Otero E; Rodríguez M; Varo E
Transplant Proc; 2009 Apr; 41(3):1003-4. PubMed ID: 19376410
[TBL] [Abstract][Full Text] [Related]
10. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
[TBL] [Abstract][Full Text] [Related]
12. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
Toso C; Meeberg GA; Bigam DL; Oberholzer J; Shapiro AM; Gutfreund K; Ma MM; Mason AL; Wong WW; Bain VG; Kneteman NM
Transplantation; 2007 May; 83(9):1162-8. PubMed ID: 17496530
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus in renal transplantation.
Morath C; Arns W; Schwenger V; Mehrabi A; Fonouni H; Schmidt J; Zeier M
Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii61-viii65. PubMed ID: 17890266
[TBL] [Abstract][Full Text] [Related]
14. The role and value of sirolimus administration in kidney and liver transplantation.
Mehrabi A; Fonouni H; Kashfi A; Schmied BM; Morath Ch; Sadeghi M; Schemmer P; Encke J; Sauer P; Zeier M; Weitz J; Büchler MW; Schmidt J
Clin Transplant; 2006; 20 Suppl 17():30-43. PubMed ID: 17100699
[TBL] [Abstract][Full Text] [Related]
15. The impact of mTOR inhibitors on the development of malignancy.
Geissler EK
Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
[TBL] [Abstract][Full Text] [Related]
16. [Minimize kidney failure in transplantation patients with proliferation signal inhibitors].
Glowacki F; Dharancy S; Noël C; Hazzan M
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S253-6. PubMed ID: 20004331
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus as rescue therapy after liver transplantation.
Reigada CH; de Ataide EC; de Araújo FR; Ramos AP; Stucchi RS; Eescanhoela CA; Boin IF
Transplant Proc; 2012 Oct; 44(8):2434-7. PubMed ID: 23026613
[TBL] [Abstract][Full Text] [Related]
18. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
[TBL] [Abstract][Full Text] [Related]
19. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity.
Haidinger M; Hecking M; Weichhart T; Poglitsch M; Enkner W; Vonbank K; Prayer D; Geusau A; Oberbauer R; Zlabinger GJ; Soleiman A; Hörl WH; Säemann MD
Transpl Int; 2010 Aug; 23(8):777-85. PubMed ID: 20070623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
